Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial

Stock Track

Apr 29

Mesoblast Ltd's stock surged 5.12% during intraday trading on Wednesday, following the company's announcement of a key development milestone for its chronic low back pain treatment.

The biopharmaceutical company announced it has achieved the patient recruitment target in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. This milestone marks significant progress for the drug candidate, with top-line results expected in mid-2027.

Positive results from this study, designed to confirm earlier findings of pain reduction and lower opioid use, are intended to support a Biologics License Application (BLA) filing with the U.S. FDA in the third quarter of 2027. The company has highlighted this indication as a major commercial opportunity, with potential peak-year revenues exceeding USD 10 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1156659915"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156659915\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1156659915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156659915","market":"sg","top_or_hot":-1,"title":"Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial","media":"Stock Track","content":"<p>Mesoblast Ltd's stock surged 5.12% during intraday trading on Wednesday, following the company's announcement of a key development milestone for its chronic low back pain treatment.</p><p>The biopharmaceutical company announced it has achieved the patient recruitment target in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. This milestone marks significant progress for the drug candidate, with top-line results expected in mid-2027.</p><p>Positive results from this study, designed to confirm earlier findings of pain reduction and lower opioid use, are intended to support a Biologics License Application (BLA) filing with the U.S. FDA in the third quarter of 2027. The company has highlighted this indication as a major commercial opportunity, with potential peak-year revenues exceeding USD 10 billion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Soars 5.12% Intraday on Patient Recruitment Milestone in Phase 3 Back Pain Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-29 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mesoblast Ltd's stock surged 5.12% during intraday trading on Wednesday, following the company's announcement of a key development milestone for its chronic low back pain treatment.</p><p>The biopharmaceutical company announced it has achieved the patient recruitment target in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. This milestone marks significant progress for the drug candidate, with top-line results expected in mid-2027.</p><p>Positive results from this study, designed to confirm earlier findings of pain reduction and lower opioid use, are intended to support a Biologics License Application (BLA) filing with the U.S. FDA in the third quarter of 2027. The company has highlighted this indication as a major commercial opportunity, with potential peak-year revenues exceeding USD 10 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1156659915","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156659915","pubTimestamp":1777434632,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mesoblast Ltd's stock surged 5.12% during intraday trading on Wednesday, following the company's announcement of a key development milestone for its chronic low back pain treatment.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"股票追踪|Mesoblast盘中大涨5.12%背痛3期试验患者招募里程碑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"Mesoblast Ltd's stock surged 5.12% during intraday trading on Wednesday, following the company's announcement of a key development milestone for its chronic low back pain treatment.The biopharmaceutical company announced it has achieved the patient recruitment target in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. This milestone marks significant progress for the drug candidate, with top-line results expected in mid-2027.Positive results from this study, designed to confirm earlier findings of pain reduction and lower opioid use, are intended to support a Biologics License Application (BLA) filing with the U.S. FDA in the third quarter of 2027. The company has highlighted this indication as a major commercial opportunity, with potential peak-year revenues exceeding USD 10 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}